Celcuity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 3, 2026, details a significant capital raise and debt restructuring by Celcuity Inc. (CELC). The filing covers events occurring between June 3, 2026, and June 8, 2026, involving the issuance of convertible senior notes and the termination of a prior loan agreement.
Key Financial Metrics and Capital Structure
- Convertible Notes Issuance: The Company issued $575,000,000 aggregate principal amount of 0.250% Convertible Senior Notes due 2032. This includes an initial $500,000,000 offering and a full exercise of the $75,000,000 over-allotment option.
- Net Proceeds: Approximately $557.0 million in net proceeds were received after deducting underwriting discounts, commissions, and offering expenses.
- Debt Repayment: The Company voluntarily prepaid approximately $137.5 million to fully satisfy and terminate its Amended and Restated Loan and Security Agreement with Oxford Finance LLC and Innovatus Life Sciences Lending Fund I, LP.
- Interest Rate: The new Notes bear interest at 0.250% per annum, payable semi-annually starting February 1, 2027.
- Conversion Terms: Initial conversion rate is 8.0302 shares per $1,000 principal amount, equivalent to an initial conversion price of approximately $124.53 per share.
Material Changes Versus Prior Period
The filing represents a material shift in the Company's capital structure. The Company has replaced a floating-rate term loan facility (which carried a rate of Prime or 7.75% plus 2.85%, with a portion payable in kind) with a fixed-rate, low-coupon convertible debt instrument. This action eliminates the immediate interest burden of the prior loan and extends the maturity horizon to 2032, subject to conversion or redemption.
Guidance, Outlook, and Management Commentary
Use of Proceeds: Management intends to use the net proceeds primarily to repay the outstanding obligations under the terminated Loan Agreement. The remainder will be allocated to working capital and general corporate purposes, including clinical trial expenditures, commercial launch and commercialization activities, research and development, capital expenditures, and potential business acquisitions (though no binding agreements for acquisitions currently exist).
Redemption and Repurchase Rights: The Notes are redeemable by the Company on or after August 6, 2029, if the stock price exceeds 130% of the conversion price for a specified period. Holders may require the Company to repurchase the Notes at par plus accrued interest upon the occurrence of a "Fundamental Change."
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers regarding market risks and the uncertainty of future clinical and commercial milestones. The Company notes that failure to file certain SEC reports may trigger special interest accruals on the Notes.
Investor Verification Checklist
- Verify the exact net proceeds of $557.0 million against the final closing statement.
- Confirm the full extinguishment of the $137.5 million loan obligation with Oxford Finance and Innovatus.
- Monitor the Company's stock price relative to the $124.53 conversion price to assess dilution risk.
- Review the "Risk Factors" in the Company's most recent Form 10-K and 10-Q for details on clinical trial risks and liquidity constraints.
- Check for any subsequent filings regarding the use of proceeds for potential acquisitions.